Performance and Safety of the Resorbable Collagen Membrane "Ez Cure"

NCT ID: NCT03978962

Last Updated: 2025-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

56 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-28

Study Completion Date

2020-08-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The evaluation of the clinical data has demonstrated the conformity of the Resorbable Collagen Membrane (RCM), EZ CureTM, with the relevant essential requirements for its use in periodontal applications. The RCM is intended for Guided Tissue Regeneration (GTR) and Guided Bone Regeneration (GBR) procedures. It acts as a barrier against the migration of epithelial cells within the bone defect (performance) and thus complies with several surgical indications in the treatment of maxillofacial bone defects. It has been concluded that the risks associated with the use of this device are acceptable when weighted against the benefits to the patients.

In order to improve the clinical data on the RCM, the manufacturer, Biomatlante, decided to assess that the performance and safety of the device are maintained until the reaching of its intended use. In this objective, the goal of this study will be to observe the following parameters:

1. Tissue regeneration (mucosa health on the site of implantation)
2. Safety (report of any adverse event)
3. Radiographic analysis of periodontal tissues

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Bone Defect Maxillofacial Bone Defect Periodontal Bone Loss Alveolar Bone Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study population

Patients subjects to a Guided Tissue Regeneration or Guided Bone Regeneration procedure

Guided Tissue Regeneration

Intervention Type DEVICE

Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.

Covering alveolar bone defects after tooth-teeth extraction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Guided Tissue Regeneration

Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.

Covering alveolar bone defects after tooth-teeth extraction.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Guided Bone Regeneration

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged from 18 to 70
* Periodontal defects (e.g. cyst, bone tumour, crest augmentation...)
* Aleveolar bone defect after tooth (teeth) extraction
* Non opposition form (consent of the patient)
* Patients affiliated to the French social security
* Patients not under guardianship or judicial protection

Exclusion Criteria

* Pregnancy of breastfeeding women
* Severe smoker (\>10 cigarettes per day)
* Acute infections
* Allergies to the material (if an allergy of any kind is suspected, adequate exams must be carried out in advance)
* Refusal of the patient to adhere to surgical follow-up and to the limit in activity level
* Fever and/or local inflammation
* HIV positive known
* History of uncontrolled diabetes (untreated or not stabilized by treatment)
* History of treatments for previous corticosteroids, long-term (more than 6 months) and interrupted for less than 3 months
* History of chemotherapy in progress or during the last three months
* History of cervico-facial radiotherapy
* History of bone disease with disorders of blood circulation which is defined as Akbers-Schönberg disease or Paget's disease
* Known severe hyperparathyroïdism
* History of severe immune deficiency
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Atlanstat

INDUSTRY

Sponsor Role collaborator

Biomatlante

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Saïd Kimakhe, PhD, DDS

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalo-Universitaire de Nantes

Saïd Kimakhe, Phd, DDS

Role: PRINCIPAL_INVESTIGATOR

Cabinet privé

Guy Daculsi, PhD

Role: STUDY_DIRECTOR

Biomatlante

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de soins dentaires - Centre Hospitalo-Universitaire de Nantes

Nantes, , France

Site Status

Cabinet privé du Dr. S. Kimakhe

Nantes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-A03202-53

Identifier Type: OTHER

Identifier Source: secondary_id

RE-DT04-18A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.